MedTech Terms
    The authoritative reference
    All terms
    Clinical & TrialsClinical EvidenceIIT

    Investigator-Initiated Trial

    A clinical trial where an individual investigator (typically academic), not the device or drug manufacturer, holds the regulatory sponsor role and is responsible for IRB, IDE/IND, and conduct.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

    Definition

    An Investigator-Initiated Trial (IIT) is a clinical study in which an individual investigator (almost always an academic clinician) acts as the regulatory sponsor under 21 CFR 312 (drug IND) or 812 (device IDE), holding all sponsor obligations for protocol design, IRB/IEC submission, regulatory submissions, AE reporting, and study conduct. Industry support is typically limited to product supply and a financial grant under an Investigator-Initiated Research (IIR) agreement.
    What the regulation says
    21 CFR 312/812 sponsor-investigator obligations are the same as for industry sponsors, including IND/IDE filing, ICH E6 GCP compliance, IRB oversight, and AE reporting.

    What this means in practice

    IITs are an important evidence-generation channel for new use cases, expanded populations, and combination studies that the manufacturer is unlikely to fund directly. Compliance landmines arise when industry inadvertently exerts study-design control, which can convert the study into a manufacturer-sponsored trial with full PMA/labeling implications.

    Examples

    • A university physician proposes a study to evaluate a new, off-label application for an approved medical device in a rare pediatric condition, securing grant funding from a third-party foundation and receiving the devices as an in-kind donation from the manufacturer.
    • An academic research institution's cardiology department initiates a clinical trial to compare the long-term efficacy of an approved cardiovascular drug in a new patient subgroup, with the drug manufacturer providing study medication and a restricted research grant.
    • A principal investigator at a major medical center designs a study to assess the impact of an existing diagnostic imaging agent on patient outcomes when used with a novel imaging protocol, taking full responsibility for regulatory submissions and data analysis.
    Common pitfalls
    • •Industry sponsors providing too much protocol input, risks reclassification of the study as manufacturer-sponsored.
    • •Investigator-sponsors underestimating the regulatory burden they have assumed.

    Frequently asked questions

    In an Investigator-Initiated Trial (IIT), the individual academic investigator, not the manufacturer providing product or funding, holds sponsor status under 21 CFR 312 for drugs or 21 CFR 812 for devices, meaning the investigator is responsible for IND/IDE filing, IRB submission, protocol design, adverse event reporting, and overall study conduct. This distinction matters because sponsor obligations carry legal liability and FDA inspection exposure that the manufacturer does not assume simply by supplying product or grant funding.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Ecosystems (1)

    Latest in MedTech

    Sources

    3 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 1Tier 3Peer-reviewed and registry evidence· 1
    Link health: 3 verified· last checked 2026-06-20
    FDA·1eCFR·1NIH·1
    1. 1
      FDA, Investigator Responsibilities
      Tier 2 Verified
      FDAfda.gov
    2. 2
      21 CFR 312, Investigational New Drug Application
      Tier 1 Verified
      eCFRecfr.gov
    3. 3
      ClinicalTrials.gov
      Tier 3 Verified
      NIHclinicaltrials.gov

    Inline markers like [1] jump to the matching reference above.